Key Highlights

  • Acurx Pharmaceuticals shares finished the session up 18% at $1.65.
  • The FDA granted conditional acceptance of CIFBEZY as the proprietary name for ibezapolstat.
  • The name acceptance was complemented by a Trademark allowance from the USPTO.
  • The company is advancing its lead CDI antibiotic into a global Phase 3 registration program.

Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) shares finished the session up 18% at $1.65 after the company confirmed that the FDA granted conditional acceptance of CIFBEZY as the proprietary name for ibezapolstat.

What Happened

The name acceptance was complemented by a trademark allowance from the USPTO, milestones that enhance commercial preparation as the company advances its lead CDI antibiotic into a global Phase 3 registration program targeting infection resolution and recurrence prevention.

Market Reaction

Shares rose as investors responded to the commercial preparation milestones, viewing the conditional Brand name acceptance and trademark allowance as steps that support ibezapolstat's path toward eventual commercialization.

Outlook

Continued progress on the global Phase 3 registration program for ibezapolstat, targeting infection resolution and recurrence prevention in CDI, represents the next major disclosed milestone for Acurx Pharmaceuticals.